Hjem › Brystkreft › Virginia › Arlington
Kliniske studier for Brystkreft i Arlington, VA
46 studier for Brystkreft søker deltakere på steder i og rundt Arlington (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi unna
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RekruttererFase 2
- Virginia Cancer Specialists, Fairfax · 11 mi unna
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RekruttererFase 1/2
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
- Virginia Cancer Specialists, PC, Fairfax · 11 mi unna
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
RekruttererFase 3
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RekruttererFase 2
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · 11 mi unna
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RekruttererFase 3
- Inova Schar Cancer Institute ( Site 0025), Fairfax · 11 mi unna
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekruttererFase 3
- Research Site, Fairfax · 11 mi unna
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RekruttererFase 2
- Virginia Cancer Specialists, Fairfax · 11 mi unna
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekrutterer
- Inova, Fairfax · 11 mi unna
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekruttererFase 3
- Virginia Cancer Specialists, Fairfax · 11 mi unna
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekruttererFase 2
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
RekruttererFase 1
- Next Virginia, Fairfax · 11 mi unna
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekruttererFase 1/2
- NEXT Oncology, Fairfax · 11 mi unna
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekruttererFase 3
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
- Virginia Cancer Specialists, Fairfax · 11 mi unna
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Virginia Cancer Specialists, Fairfax · 11 mi unna
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi unna
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RekruttererFase 1
- NEXT Oncology, Fairfax · 11 mi unna
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RekruttererFase 1/2
- Virginia Cancer Specialists-Fairfax, Fairfax · 11 mi unna
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
RekruttererFase 1/2
- Next Oncology, Fairfax · 11 mi unna
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekruttererFase 3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi unna
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
RekruttererFase 1/2
- NEXT Virginia, Fairfax · 11 mi unna
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
- Inova Fair Oaks Hospital, Fairfax · 11 mi unna
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekruttererFase 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi unna
- Kaiser Permanente-Burke Medical Center, Burke · 11 mi unna
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- NEXT Virginia, Fairfax · 11 mi unna
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RekruttererFase 1
- NEXT Virginia, Fairfax · 11 mi unna
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekruttererFase 1
- Inova Schar Cancer Institute, Falls Church · 4 mi unna
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
- Inova Fair Oaks Hospital, Fairfax · 11 mi unna
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RekruttererFase 3
- Virginia Cancer Specialists, Fairfax · 11 mi unna
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi unna
E-Mindfulness Approaches for Living After Breast Cancer
RekruttererFase 3
- Inova Fairfax Hospital, Falls Church · 4 mi unna
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi unna
- Inova Schar Cancer Institute, Fairfax · 11 mi unna
- og 1 flere
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
RekruttererFase 1
- NEXT Virginia, Fairfax · 11 mi unna
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi unna
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
RekruttererFase 3
- INOVA Schar Cancer, Fairfax · 11 mi unna
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi unna
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- NEXT, Fairfax · 11 mi unna
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
RekruttererFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi unna
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
RekruttererFase 1/2
- Inova Schar Cancer Institute ( Site 0051), Fairfax · 11 mi unna
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RekruttererFase 3
- Virginia Cancer Specialists, PC, Reston · 14 mi unna
- Virginia Cancer Specialists, Manassas · 22 mi unna
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
RekruttererFase 1
- Virginia Cancer Specialists, Fairfax · 11 mi unna
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RekruttererFase 1
- NEXT Oncology Virginia, Fairfax · 11 mi unna
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekruttererFase 1/2
- NEXT Virginia, Fairfax · 11 mi unna
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekruttererFase 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi unna
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RekruttererFase 1/2
- NEXT, Virginia, Fairfax · 11 mi unna
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekruttererFase 1
- Inova Schar Cancer Center, Fairfax · 11 mi unna
- NEXT Virginia, Fairfax · 11 mi unna
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
RekruttererFase 1
- Biotheryx Investigative Site, Fairfax · 11 mi unna
Brystkreft-studier i andre byer
- New York City, NY134 studier
- Houston, TX126 studier
- Boston, MA111 studier
- Nashville, TN80 studier
- Los Angeles, CA72 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Durham, NC63 studier
- Queens, NY63 studier
- Chicago, IL58 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Arlington
- Ikke-småcellet lungekreft104 studier
- Metastatisk kreft53 studier
- Kolorektal kreft52 studier
- Kreft (alle typer)48 studier
- Eggstokkreft46 studier
- Lungekreft41 studier
- Endometriekreft39 studier
- Pankreaskreft33 studier
- Plateepitelcancer i hode og hals26 studier
- Småcellet lungekreft23 studier
- Tripelnegativ brystkreft20 studier
- Mavekreft20 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.